Oppenheimer analysts are weighing in on the Cambridge-based fertility company OvaScience Inc (NASDAQ:OVAS) and biopharmaceutical company Rockwell Medical Inc (NASDAQ:RMTI), with positive ratings.
In a research report released Wednesday, Oppenheimer analyst Rohit Vanjani reiterated an Outperform rating on shares of OvaScience, while raising the price target to $16 (from $12), after attending the American Society for Reproductive Medicine (ASRM) meeting in Baltimore, MD.
Vanjani observed, “Though OvaScience’s private event and presentation were limited to practitioners and researchers only, and closed to the Street, we were still able to get some important takeaways from a few experts at the conference. We continue to believe that different clinics will use AUGMENT in different ways. While the clinician from the Canada site offering AUGMENT believes that procedures will be more beneficial in refractory patients under 40 years old, a potential AUGMENT clinician from Japan believes the procedure can be used in an older patient population and in some cases in first-line. We came away from the meeting at least more confident in OvaScience’s launch plans.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Rohit Vanjani has a total average return of 24.1% and a 65% success rate. Vanjani has a -31.7% average return when recommending OVAS, and is ranked #51 out of 3795 analysts.
As of this writing, all the 5 analysts polled by TipRanks rate OvaScience stock a Buy. With a return potential of 295%, the stock’s consensus target price stands at $57.60.
Rockwell Medical Inc
Oppenheimer analyst Ling Wang reiterated an Outperform rating on Rockwell, with a price target of $26, as the company will have four poster presentations during the upcoming American Society of Nephrology (ASN) Kidney Week November 3-8 in San Diego.
Wang noted, “Triferic continues to show favorable efficacy and safety profile in long-term expansion phase III studies. A pooled analysis across two phase III and multiple OL or controlled phase II trials showed Triferic’s safety profile similar to that of placebo. We continue to believe Triferic potentially offers both clinical and cost benefits over IV iron and expect ASN to be an excellent forum to showcase Triferic to dialysis providers and nephrologists. We expect top-line growth, a fast path to profitability and potential business development activities to drive the shares.”
According to TipRanks.com, analyst Ling Wang has a total average return of -9.4% and a 31.5% success rate. Wang has a -2.7% average return when recommending RMTI, and is ranked #3627 out of 3795 analysts.
Out of the 5 analysts polled by TipRanks in the last three months, 1 rates Rockwell stock a Buy, while 2 rate the stock a Sell. With a return potential downside of nearly 48%, the stock’s consensus target price stands at $5.50.